The following statement by PH in today's announcement regarding the appointment of Kim Drapkin as Non-Executive Director, stands out to me as significant and a possible indicator of future company investment and expansion plans. This is particularly telling in light of Kim's extensive experience, 'with more than 25 years of experience in the biotechnology and pharmaceutical sectors, Ms Drapkin possesses a strong background in finance, capital raising, and strategic financial planning'. IMO this further suggests Imugene are very confident in the progress of their clinical trials to date, and the potential success of their IP overall.
The following statement by PH in today's announcement regarding...
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $373.3M | |||
| Open | High | Low | Value | Volume |
| 5.1¢ | 5.2¢ | 4.9¢ | $1.384M | 27.31M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1302118 | 5.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.2¢ | 528865 | 4 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |